Supporting information for

Enhanced Anticancer Potency by Acid-responsive ZnO Incorporated Liposomal Drug Delivery

Nirmalya Tripathy,^a Rafiq Ahmad, ^b Hyun Ah Ko,^a Gilson Khang,^a and Yoon-Bong Hahn^{b,*}

^a Department of BIN Fusion Technology and Polymer BIN Research Center, Chonbuk National University, 567 Baekjedaero, Deokjin-gu, Jeonju 561-756, Republic of Korea

^b School of Semiconductor and Chemical Engineering, and Nanomaterials Processing Research Center, Chonbuk National University, 567 Baekjedaero, Deokjin-gu, Jeonju 561-756, Republic of Korea

* Corresponding author. Tel.: +82 63 2702439; fax: +82 63 2702306

E-mail: <u>ybhahn@chonbuk.ac.kr</u> (Y. B. Hahn)



Figure S1. Concentration-absorbance standard curve for free DNR concentration at 480 nm (optical path = 1 cm). Solid line is the liner fit obtained by the analysis tool in Origin software.



Figure S2. TEM image of uranyl acetate stained ZNPs-Liposome nanocomplex.



Figure S3. (a) UV-visible absorption and (b) PL spectra of ZNPs-Liposome and bare liposome.



Figure S4. Flow cytometric analysis of the total intracellular fluorescence intensity in A549 cells after 6 h exposure to free DNR (b1-b4), Liposome-DNR (c1-c4) and ZNPs-Liposome-DNR (d1-d4) nanocomplexes at different concentrations. (c1) 3.125µg/mL Liposome-DNR with 0.045µg/mL DNR; (c2) 6.25µg/mL Liposome-DNR with 0.09µg/mL DNR; (c3) 12.5µg/mL Liposome-DNR with 0.181µg/mL DNR; (c4) 25µg/mL Liposome-DNR with 0.36µg/mL DNR. (d1) 3.125µg/mL ZNPs-Liposome-DNR with 0.104µg/mL DNR; (d2) 6.25µg/mL ZNPs-Liposome-DNR with 0.209µg/mL DNR; (d3) 12.5µg/mL ZNPs-Liposome-DNR with 0.42µg/mL DNR; (d4) 25µg/mL ZNPs-Liposome-DNR with 0.83µg/mL DNR.